Ensuring a reliable supply of critical medications when they're needed most. Sterile compounded medications manufactured to address drugs listed on the FDA Drug Shortage List.
Become a Provider
Sterile compounded medications manufactured by our 503B outsourcing facility to address drugs listed on the FDA Drug Shortage List. These products are developed and manufactured in full compliance with Section 503B of the Federal Food, Drug, and Cosmetic Act and current Good Manufacturing Practices (cGMP).
The purpose is to support hospitals, emergency departments, surgery centers, and clinics by ensuring a reliable supply of critical medications that are temporarily unavailable or insufficient in the commercial market.
Production is initiated only when a drug is officially listed on the FDA Drug Shortage List or when otherwise permitted under FDA guidance. Products are prioritized based on clinical necessity, patient safety, and public health impact.
This category is dynamic and responsive, meaning product offerings may be added or discontinued based on changes to the FDA Drug Shortage List, regulatory guidance, and healthcare system needs.
Ready-to-use sterile injectable medications for immediate clinical application.
Pre-filled syringes designed for rapid administration in emergency and acute care settings.
Intravenous solutions for hydration, nutrition, and therapeutic support.
Specialized formulations for sensitive applications in acute care and emergency settings.
Critical medications for emergency departments and urgent care scenarios.
Formulations commonly used in hospitals, surgery centers, and clinical environments.
At New Era Global, we understand that medication shortages can have life-or-death consequences. Our FDA Drug Shortage Products program is designed to be responsive and dynamic, ensuring healthcare providers have access to the critical medications their patients need.
Contact our team to learn about current availability and how we can support your healthcare institution.